An abuse-resistant patch for transdermally delivering an opioid to a subject, comprising: (a) a backing layer; (b) a first layer underlying the backing layer, the first layer comprising: an opioid antagonist; wherein the backing layer is substantially impermeable to the opioid antagonist of the first layer; (c) a second layer underlying the first layer, the second layer comprising: (i) an opioid selected from the group consisting of: an opioid agonist, an opioid agonist-antagonist and an opioid agonist-antagonist prodrug which is a buprenorphine prodrug; (ii) a pressure sensitive adhesive; and (d) a barrier layer located between the first and second layer, the barrier layer comprising: a water-insoluble polymeric material and a water-soluble polymer; wherein the release ratio is between 1:60 and 60: 1 after the patch has been placed in ethanol, water or a phosphate buffer having a pH of 6.5 for greater than 30 seconds; wherein the opioid agonist is selected from the group consisting of: alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, dihydroetorphine, fentanyl, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levorphanol, levomethadyl, levophenacylmorphan, lofentanil, meperidine, metazocine, methadone, metopon, morphine, myrophine, narceine, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, phenadoxone, phenomorphan, phenazocine, phenoperidine, piminodine, piritramide, ropheptazine, promedol, properidine, propoxyphene, sufentanil, tilidine and tramadol introduce a gap or a pharmaceutically acceptable salt thereof; or wherein the opioid agonist-antagonist is selected from the group consisting of: buprenorphine, butorphanol, dezocine, meptazinol, nalbuphine, nalorphine and pentazocine or a pharmaceutically acceptable salt thereof; or wherein the opioid agonist-antagonist prodrug is a buprenorphine prodrug selected from the group consisting of: or a pharmaceutically acceptable salt thereof, and wherein the opioid antagonist is selected from the group consisting of: naltrexone and naloxone or a pharmaceutically acceptable salt thereof. (a) a backing layer; (b) a first layer underlying the backing layer, the first layer comprising: an opioid antagonist; wherein the backing layer is substantially impermeable to the opioid antagonist of the first layer; (c) a second layer underlying the first layer, the second layer comprising: (i) an opioid selected from the group consisting of: an opioid agonist, an opioid agonist-antagonist and an opioid agonist-antagonist prodrug which is a buprenorphine prodrug; (ii) a pressure sensitive adhesive; and (i) an opioid selected from the group consisting of: an opioid agonist, an opioid agonist-antagonist and an opioid agonist-antagonist prodrug which is a buprenorphine prodrug; (ii) a pressure sensitive adhesive; and (d) a barrier layer located between the first and second layer, the barrier layer comprising: a water-insoluble polymeric material and a water-soluble polymer; buprenorphine, butorphanol, dezocine, meptazinol, nalbuphine, nalorphine and pentazocine or a pharmaceutically acceptable salt thereof; or wherein the opioid agonist-antagonist prodrug is a buprenorphine prodrug selected from the group consisting of: or a pharmaceutically acceptable salt thereof, and wherein the opioid antagonist is selected from the group consisting of: naltrexone and naloxone or a pharmaceutically acceptable salt thereof.